000			03780nam a22005295i 4500
001			978-3-540-26670-9
003			DE-He213
005			20161121230703.0
007			cr nn 008mamaa
008			100301s2005 gw | s |||| 0|eng d
020			_a9783540266709 _9978-3-540-26670-9
024	7		_a10.1007/b137900 _2doi
050		4	_aRM1-950
072		7	_aMMG _2bicssc
072		7	_aMED071000 _2bisacsh
082	0	4	_a615 _223
245	1	0	_aInhibitors of Protein Kinases and Protein Phosphates _h[electronic resource] / _cedited by Lorenzo A. Pinna, Patricia T.W. Cohen.
246	3		_awith contributions by numerous experts
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2005.
300			_aX, 458 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v167
505	0		_aProtein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems -- General Aspects of PKs Inhibition -- New Design Strategies for Ligands That Target Protein Kinase-Mediated Protein-Protein Interactions -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases -- The Paullones: A Family of Pharmacological Inhibitors of Cyclin-Dependent Kinases and Glycogen Synthase Kinase 3 -- Pharmacological Potential of p38 MAPK Inhibitors -- Inhibitors of PKA and Related Protein Kinases -- Inhibitors of Protein Kinase CK2: Structural Aspects -- Aminoglycoside Kinases and Antibiotic Resistance -- Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases -- Protein Tyrosine Phosphatases as Therapeutic Targets -- Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors -- Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target -- Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity -- Inhibitors in Clinical Use or Advanced Clinical Trials -- Clinical Immunosuppression using the Calcineurin-Inhibitors Ciclosporin and Tacrolimus -- Targeted Therapy with Imatinib: An Exception or a Rule? -- Clinical Aspects of Imatinib Therapy -- Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti-Rho-Kinase Therapy -- Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase.
520			_aThe aims of this volume are to highlight the tremendous pharmacological potential of protein kinase and protein phosphatase inhibitors, to provide a thorough overview of the most remarkable achievements in the field and to illustrate how beneficial these studies can be for the advancement of both basic knowledge on biological regulation and deregulation and for the clinical treatment of a wide spectrum of diseases. This goal is attained by contributions of leader investigators in the field, who address the issue from different angles.
650		0	_aMedicine.
650		0	_aPharmacology.
650		0	_aOncology.
650		0	_aMedical biochemistry.
650		0	_aPathology.
650	1	4	_aBiomedicine.
650	2	4	_aPharmacology/Toxicology.
650	2	4	_aOncology.
650	2	4	_aPathology.
650	2	4	_aMedical Biochemistry.
700	1		_aPinna, Lorenzo A. _eeditor.
700	1		_aCohen, Patricia T.W. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540212423
830		0	_aHandbook of Experimental Pharmacology, _x0171-2004 ; _v167
856	4	0	_uhttp://dx.doi.org/10.1007/b137900
912			_aZDB-2-SBL
950			_aBiomedical and Life Sciences (Springer-11642)
999			_c502464 _d502464